613134 / Market Consultation, Large Cancer Panel Test HUS 324-2025
Tiivistelmä
Katso samankaltaisia mahdollisuuksia
Kaikkien tietojen näyttäminen vaatii rekisteröitymisen ja kirjautumisen palveluun.
613134 / Market Consultation, Large Cancer Panel Test HUS 324-2025
Hankintailmoitustyyppi
Suunnittelu [E1]
Julkaistu
9.5.2026
18.12
(UTC+03:00)
Kysymysten jätön määräaika
14.5.2026
12.00
(UTC+03:00)
Vastausten määräaika
21.5.2026
12.00
(UTC+03:00)
Organisaatio
HUS-yhtymä
Kuvaus
This document is not a contract notice or a call for tenders, but a market consultation in accordance with Section 65 of the Finnish Procurement Act, carried out by the contracting authority (also "HUS Group" and "Client") as described in this request for information.
The purpose of this request for information is to clarify issues related to the procurement referred to in the title. The objective of the request is to obtain comprehensive information on the subject matter of the procurement in order to support the preparation of the procurement, so that any potential competitive tendering procedure can be conducted in the most appropriate manner possible.
The contracting authority does not commit to carrying out the procurement. Decisions on whether to initiate a possible procurement process will be made after the market consultation.
Summary of the description of the procurement:
The HUS Group requests tenders for a large cancer panel test (also "product") for HUS Diagnostic Center.
Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic genetic testing services to all patients at Helsinki and Uusimaa Hospital District. The services include analysis of both constitutional samples and malignancies. The laboratory provides sequencing services mainly using local sequencing capacity (Illumina NovaSeq 6000, NovaSeq X Plus, Ion GeneStudio S5 Prime equipment).
The large cancer panel test is intended for detection of small nucleotide variants (SNVs), indels, gene fusions, copy number variations (CNVs), microsatellite instability (MSI), homologous recombination deficiency (HRD), and tumor mutation burden (TMB) relevant for the genetic profiling of solid tumor samples and/or hematological malignancies as well as plasma samples for cfDNA analysis.
The procurement is divided into LOT A and LOT B:
LOT A
- This lot contains panels for solid tumors and hematological malignancies and analysis software.
- This lot includes an option for special panel for salivary gland tumors and an option custom panel.
- The HUS Group will decide separately on the use of the option.
LOT B
- This lot contains panel for cell-free DNA and analysis software.
- This test is based on analysis of total nucleic acids (RNA and/or DNA) extracted from paraffin embedded specimens and/or fresh-frozen specimens and from plasma samples.
For more information please read the Appendixes.